FIG 6.

Fatty acid sources demonstrate variable protection from daptomycin in daptomycin-sensitive (S613) and daptomycin-resistant (R712) clinical pair isolates. Shown are the averages ± standard deviations for n = 3. (A) Bile-supplemented S613 challenged with 10 μg/ml daptomycin or R712 challenged with 40 μg/ml daptomycin. S613 supplemented with 0.2% bile had statistically increased numbers of survivors versus those of its unsupplemented counterparts at all time points analyzed (P ≤ 0.037). (B) Serum supplementation and challenge with 10 μg/ml or 40 μg/ml daptomycin. S613 supplemented with 15% sera had a statistically increased number of survivors versus that of its unsupplemented counterpart at all time points analyzed (P values ≤ 0.0001), while the R712 supplemented cultures were not significantly different (P > 0.05). (C) Oleic acid (OA) supplementation and challenge with 10 μg/ml or 40 μg/ml daptomycin. All strains supplemented with 20 μg/ml OA had statistically increased numbers of survivors versus those of their unsupplemented counterparts at all time points analyzed (P ≤ 0.002).